Quick Answer
Avalo Therapeutics, Inc. reported R&D Expense of $5.79 million for fiscal year 2018.
Avalo Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2018 | $5.79M | +32.3% |
| 2017 | $4.37M | -56.9% |
| 2016 | $10.15M | +54.1% |
| 2015 | $6.59M | -46.2% |
| 2014 | $12.24M | +37.3% |
| 2013 | $8.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2019 | $3.40M | +106.2% | +214.1% |
| June 30, 2018 | $1.08M | +119.3% | -34.4% |
| March 31, 2018 | $1.65M | +73.1% | +71.0% |
| September 30, 2017 | $964.6K | -78.9% | +95.4% |
| June 30, 2017 | $493.6K | -80.3% | -48.2% |
| March 31, 2017 | $953.1K | -58.4% | -79.2% |
| September 30, 2016 | $4.58M | +270.3% | +83.1% |
| June 30, 2016 | $2.50M | +33.4% | +9.1% |
- Avalo Therapeutics, Inc. showed an increase of +32.3% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2018 period, Avalo Therapeutics, Inc.’s r&d expense has declined by 35.1% (from $8.91 million to $5.79 million).
- The most recent figure is from Avalo Therapeutics, Inc.’s fiscal year 2018 report (Form 10-K), filed with the SEC on March 18, 2019.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: